Aminergic systems in Alzheimer's disease and Parkinson's disease.
Biochemical markers for serotoninergic and catecholaminergic neurons in frontal and temporal poles were examined post mortem in brains of patients with Alzheimer's disease, Parkinson's disease, and the two combined. Binding of [3H] citalopram to serotoninergic uptake sites and levels of serotonin were decreased by 40 to 50% in brains of persons in each disease category. In contrast, significant reductions of catecholaminergic markers were not detected. In all three disease groups, the choline acetyltransferase activity was reduced by 50 to 60%. Binding sites for adenosine (A1), muscarinic cholinergic, phencyclidine, beta-adrenergic, and calcium antagonist receptors were unchanged. We conclude that substantial damage to serotoninergic neurons occurs in persons with Parkinson's and Alzheimer's diseases.
D000544:Alzheimer Disease / Q000378:metabolism; D001679:Biogenic Amines / Q000378:metabolism*; D001921:Brain / Q000201:enzymology / Q000378:metabolism; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D015283:Citalopram; D006801:Humans; D007099:Imipramine / Q000378:metabolism; D008454:Mazindol / Q000378:metabolism; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000378:metabolism*; D011437:Propylamines / Q000378:metabolism; D012016:Reference Values; D012701:Serotonin / Q000378:metabolism; D014018:Tissue Distribution
D001679:Biogenic Amines; D011437:Propylamines; D015283:Citalopram; D012701:Serotonin; D008454:Mazindol; D002795:Choline O-Acetyltransferase; D007099:Imipramine; D009638:Norepinephrine